Table 1.
Patient characteristics stratified by cardiovascular exposures of interest
| Patient characteristics | Total (n = 4090) | Ischemic heart disease (n = 541) | Heart failure (n = 271) | Atrial fibrillation (n = 479) |
|---|---|---|---|---|
| Age | 63.5 (14.9) | 73.4 (11.6) | 76.9 (11.3) | 77.6 (11.1) |
| Sex | 2043 (50.0) | 333 (61.6) | 162 (59.8) | 266 (55.5) |
| Ischaemic heart disease | 541 (13.2) | 470 (100.0) | 151 (55.7) | 163 (34.0) |
| Heart failure | 271 (6.6) | 151 (27.9) | 236 (100.0) | 149 (31.1) |
| Atrial fibrillation | 479 (11.7) | 163 (30.1) | 149 (55.0) | 401 (100.0) |
| COPDa | 627 (15.3) | 143 (26.4) | 99 (36.5) | 131 (27.3) |
| Diabetes | 598 (14.6) | 169 (31.2) | 100 (36.9) | 121 (25.3) |
| Chronic kidney disease | 293 (7.2) | 102 (18.9) | 77 (28.4) | 86 (18.0) |
| Cancer | 423 (10.3) | 73 (13.5) | 43 (15.9) | 83 (17.3) |
| Hypertension | 1281 (31.3) | 369 (68.2) | 233 (86.0) | 324 (67.6) |
| Stroke | 389 (9.5) | 100 (18.5) | 64 (23.6) | 116 (24.2) |
| Liver disease | 111 (2.7) | 15 (2.8) | 9 (3.3) | 10 (2.1) |
| Beta-blockers | 641 (15.7) | 261 (48.2) | 180 (66.4) | 264 (55.1) |
| Calcium channel Blockers | 571 (14.0) | 123 (22.7) | 32 (11.8) | 87 (18.2) |
| Ras inhibitor | 1029 (25.2) | 251 (46.4) | 147 (54.2) | 179 (37.4) |
| Loop diuretics | 486 (11.9) | 182 (33.6) | 166 (61.3) | 189 (39.5) |
| Asprin | 401 (9.8) | 208 (38.4) | 72 (26.6) | 43 (9.0) |
| Statin | 942 (23.0) | 316 (58.4) | 133 (49.1) | 190 (39.7) |
| Anticoagulation | 446 (10.9) | 146 (27.0) | 137 (50.6) | 328 (68.5) |
aCOPD, chronic obstructive pulmonary disease.